ArticleJournal of acquired immune deficiency syndromes (1999)2017
Brief Report: Should Abacavir Be a First-Line Alternative for Adults With HIV in Sub-Saharan Africa?
Guinevere Q Lee, Suzanne McCluskey, Yap Boum, Peter W Hunt, Jeffrey N Martin, David R Bangsberg, Xiaojiang Gao, P Richard Harrigan, Jessica E Haberer, Mark J Siedner
Article in Journal of acquired immune deficiency syndromes (1999), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 8 institutions in 3 countries.
Guinevere Q Lee*BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada; †Department of Infectious Diseases, Massachusetts General Hospital, Boston, MA; ‡Harvard University Center for AIDS Research, Harvard Medical School, Boston, MA; §Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda; ‖HIV/AIDS division, University of California, San Francisco, CA; ¶Gladstone Institute of Virology and Immunology, University of California, San Francisco, CA; #School of Public Health, Oregon Health Sciences University, Portland, OR; and **Center for Cancer Research, National Cancer Institute, Frederick, MD.
Suzanne McCluskey
Yap Boum
Peter W Hunt
Jeffrey N Martin
David R Bangsberg
Xiaojiang Gao
P Richard Harrigan
Jessica E Haberer
Mark J Siedner
Harvard University · USMbarara University of Science and Technology · UGAIDS Vancouver · CACenter for Cancer Research · USGladstone Institutes · USMassachusetts General Hospital · USOregon Health & Science University · USUniversity of California, San Francisco · US
Funding
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
TB PREVENTION AND HIV IN THE HOMELESS--AN INTERVENTIONR01MH054907 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BANGSBERG, DAVID ROY · 1995 to 2014
$20.7M
West Coast AIDS and Cancer Specimen Resource (ACSR)U01CA066529 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCGRATH, MICHAEL SHANNON · 1994 to 2012
$16.1M
PROGRAM FOR AIDS CLINICAL RESEARCH TRAINING (PACRT)T32AI007433 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MARK J SIEDNER · 1992 to 2026
$11.4M
Multidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8M
Alcohol use and ARV treatment outcomes in UgandaR21AA014784 · NIAAA · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI BANGSBERG, DAVID ROY · 2003 to 2005
$1.2M
Behavioral Aspects of Low-cost Medical Devices to Improve HIV CareK23MH099916 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI SIEDNER, MARK J · 2013 to 2017
Despite a poor toxicity profile, zidovudine supersedes abacavir (ABC) as an alternative first-line agent in most international treatment guidelines because of concerns about HLA-B*57:01-related ABC-hypersensitivity. We detected one case of HLA-B*57:01 carriage among 513 HIV-infected individuals in Uganda, which, in combination with previous reports, supports the safety of ABC in the region.
Indexed as
AbacavirAdultAfrica South of the SaharaAnti-HIV AgentsCD4 Lymphocyte CountCohort StudiesDideoxynucleosidesFemaleFollow-Up StudiesGenotyping TechniquesHIV-1HIV InfectionsHLA-B AntigensHumansMalePilot ProjectsAbacavirAnti-HIV AgentsDideoxynucleosidesHLA-B*57:01 antigenHLA-B Antigens
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Brief Report: Should Abacavir Be a First-Line Alternative for Adults With HIV in Sub-Saharan Africa? · full record | OpenQuestion